Background: In acute coronary syndrome, the use of intravenous insulin infusions (IVII) to control hyperglycaemia is based on limited evidence of survival benefit. Aims: To compare 7 day survival for patients receiving IVII compared with those receiving routine care to control admission hyperglycaemia (>=11 mmol/l) in acute coronary syndrome. Methods and results: We used matched propensity analysis to examine observational data from the MINAP database between 2008 and 2012. We matched 5974 pairs of patients. We separately examined outcomes for ST elevation (STEMI) and non ST segment elevation (NSTEMI) infarctions, and those without known diabetes and those with type 2 diabetes. Survival benefit from the use of IVII was seen only in patients with STEMI not known to have diabetes at admission (adjusted hazard ratio (HR) 0.77 (95% confidence interval (CI) 0.64-0.92), p=0.005). Those with STEMI and existing type 2 diabetes who received IVII showed similar outcomes to routine care (HR 0.99 (95% CI 0.80-1.23), p=0.931). In patients with NSTEMI IVII was associated with significantly worse adjusted 7 day survival outcome than routine care, regardless of diabetes status; for those without known diabetes, HR 1.50 (95% CI 1.04-2.16), p=0.029, and for those with type 2 diabetes, HR 1.35 (95% CI 1.08-1.70), p=0.010. Conclusion: As used in current clinical practice to treat hyperglycaemia in acute coronary syndromes, IVII appears to be of benefit only for patients with STEMI who are not known to have diabetes. IVII is associated with adverse early outcomes in patients with NSTEMI.
Introduction
In acute coronary syndrome (ACS), higher levels of blood glucose at admission are associated with lower survival rates, [1] [2] [3] and the unadjusted relative risk of death is substantially higher for those not known to have diabetes compared with those having a prior diagnosis of diabetes for any elevated level of admission glucose. 4 Normalisation of glucose after admission is associated with better survival in hyperglycaemic patients with ACS whether or not they are treated with insulin. 5, 6 However, randomised studies that have examined the impact on mortality of lowering blood glucose with intravenous insulin infusions (IVII) have presented conflicting results, [7] [8] [9] with the evidence for benefit resting on a single randomised study that combined in-hospital IVII with intense post-discharge glycaemic control.
Despite the limited evidence base, national clinical guidelines currently recommend IVII for ACS presenting with hyperglycaemia. [10] [11] [12] [13] [14] However, there is presently no evidence that survival benefit applies across the spectrum of ACS. Previous randomised studies [7] [8] [9] have examined a mixed cohort of ST segment elevation (STEMI) and non ST elevation infarctions (NSTEMI) that, while predominantly comprised of patients having type 2 diabetes, also included hyperglycaemic patients without a prior diagnosis of diabetes and, in one study, patients having type 1 diabetes. 7 No previous randomised study has compared the impact of IVII in those without known diabetes with those having a prior diagnosis of type 2 diabetes, of whom the majority would be receiving glucose lowering medication at the time of the infarction. In addition it is not known, in an era of increasingly sensitive troponin assays, if NSTEMI respond to IVII in a similar manner to STEMI.
We therefore used data from the National Audit of Myocardial Ischaemia Project (MINAP) database 15 to examine the effect of IVII in patients with ACS presenting with glucose >=11 mmol/l in the context of contemporary clinical practice in England and Wales. We examined survival benefit from the use of IVII compared to routine care in those not known to have diabetes and in those with type 2 diabetes, and separately for STEMI and NSTEMI. In order to assess the effect of IVII without any additional effect of intense post-discharge glycaemic control, we examined survival to 7 days following admission.
Methods
The MINAP database contains details of ACS admissions to hospitals in England and Wales. 15 The database records information on patient co-morbidity and management for both STEMI and NSTEMI, and for the purposes of this study provided information on admission blood glucose, type of diabetes, and pre-hospital and inpatient management of hyperglycaemia. Fully anonymised data were extracted from the MINAP database and included records from all hospitals in England and Wales (n=220) accepting emergency admissions between January 2008 and March 2012. The United Kingdom Office of National Statistics provided mortality status.
Patient cohort
We examined management and outcomes for first admissions having a final diagnosis of troponin positive ACS, either with or without STEMI, and who had an admission blood glucose within the range of 11 to 50 mmol/l (to convert to mg/dl multiply by 18.1). ACS were categorised as STEMI and NSTEMI based on biomarker and electrocardiographic criteria. Patients had either preexisting type 2 diabetes treated before admission with dietary restrictions or oral medication with or without additional subcutaneous insulin, or were not known to have diabetes at the time of admission. Treatment allocation to IVII or routine care was determined by the attending physician. Insulin infusions were prescribed according to local practice and were not standardised. Blood glucose was measured either by bedside analysis or in the laboratory. Patients having subcutaneous insulin in hospital were excluded from analysis.
Statistical analysis
We examined the distributions of baseline variables of patient characteristics, cardiovascular risk factors and glucose levels and medication at hospital admission between patients receiving routine care and IVII. Categorical variables were summarised using frequencies and percentages and a χ 2 test was used to compare the differences between the two groups. We used the median and interquartile range (IQR) for continuous variables, with the Mann-Whitney test for differences. As preliminary analyses demonstrated significant differences in clinical characteristics between those receiving IVII and those receiving routine care, a multivariate logistic regression model was developed, based on important clinical features or those features having statistical significance on univariate analysis (p<0.001), in order to calculate a propensity score for the probability of being treated with IVII. We used the following variables: age, gender, admission blood glucose as a categorical variable (11-12, 12-14,14-16,16-18,18-20 and >=20 mmol/l.), type of infarction (NSTEMI/STEMI), a previous history of myocardial infarction, hypertension, hyperlipidaemia, chronic renal failure (creatinine >200 µm/l), chronic obstructive pulmonary disease, peripheral vascular disease, diabetes status, prescription of a loop diuretic (as a surrogate for development of heart failure during admission), 16 use of angiography, 17 and primary reperfusion strategy for STEMI (thrombolytic treatment, primary percutaneous coronary intervention (pPCI) or no reperfusion treatment). Each patient received a propensity score between 0 and 1 for the probability of being treated with IVII. We then matched the propensity score to within 0.01 between patients having IVII and routine care using 1:1 matching criteria. Multivariate adjusted Cox regression models were then used to examine the effects of IVII on survival to 7 days after admission for those with STEMI and those with NSTEMI, and for patients with and without diabetes. The following covariates were also used in these models: treatment before admission with aspirin, angiotensin converting enzyme (ACE) inhibitors or receptor blockers, beta blockers, thienopyridines and statins, previous PCI, previous coronary artery bypass grafting and current cigarette smoking. In the adjustment analysis any missing data amongst the variables were coded and included in analysis. We tested for an interaction effect between IVII and routine care on mortality for STEMI and NSTEMI, and for those with diabetes and those not known to have diabetes, using a 2-sided p value, and calculated the ratio of HRs for survival benefit with IVII. 18 Analyses in this study were performed using the SAS statistical program (SAS Version 9.2, SAS Institute Inc., Cary, NC, USA).
Results
From the 36,738 records of patients admitted to hospitals in England and Wales between January 2008 and March 2012 with admission glucose between 11 and 50 mmol/l, we identified 23,506 patients who had either type 2 diabetes or who were not known to have diabetes, for whom an explicit management strategy for hyperglycaemia was recorded. Of these, 70.3% (16,520) received routine care and 29.7% (6986) had IVII ( Figure 1 ). Of 23,506 patients, 51.2% (12,041) had type 2 diabetes and 48.8% (11,465) were not known to have diabetes at admission; 43.5% (10,216) had STEMI and 56.5% (13,290) had NSTEMI. The distribution of STEMI and NSTEMI in relation to diabetes status and the use of IVII are shown in Table 1 . While IVII was used for 29.7% patients overall, it was used substantially more frequently for those with existing diabetes, 41.6% (5007 of 12,041) than for those not known to have diabetes, 17.3% (1979 of 11,465).
Patient characteristics for the whole cohort are shown in Table 2 . Those receiving IVII and those receiving routine care differed in several important respects. Those receiving IVII were significantly younger and were more likely to be male. They also had a higher median admission glucose (15.8 mmol/l against 13 mmol/l). Those having STEMI were also more likely to receive insulin than those with NSTEMI. Data on other clinical characteristics appear in online data table e1 and show further significant differences in previous medical conditions, pre-hospital medication and in-hospital care. In view of these differences, and the substantially greater use of IVII for those with known diabetes, we used matched propensity analysis to compare survival at 7 days following admission between those having IVII and those having routine care. Of 6986 patients having IVII 5974 (85.5%) were matched 1:1 with patients having routine care. The clinical characteristics of the matched cohort are shown in Table 3 . There were no significant differences in clinical characteristics, except that a slightly higher proportion of patients with type 2 diabetes received routine care and a higher proportion used beta blockers before admission.
Survival outcome at 7 days
The 7 day mortality for all hyperglycaemic patients with STEMI was 14.6% (819 of 5608). For those with type 2 diabetes it was 11% (338 of 3081) and for those not known to have diabetes it was 19% (481 of 2527 (Table 4 ). An interaction analysis showed that the survival benefit effect of IVII was significantly more powerful for those with STEMI compared to NSTEMI; the ratio of HRs was 0.60 (95% CI 0.47-0.76), p<0.001 overall, 0.51 (95% CI 0.34-0.77), p=0.001 in patients without known diabetes and 0.73 (95% CI 0.54-1.01), p=0.052 in patients with known diabetes.
Sensitivity analyses
We performed a sensitivity analysis by excluding those patients who had any missing data in any of the variables used for adjustment (all records had vital status). The number of patients in the analysis was 8746, 73.2% of 11,948 propensity matched patients. There were no significant differences in those included between between IVII and routine care groups, and analyses showed similar overall results to those in Table 3 (see also Table e2 ). However, the benefits of routine care on survival seen for NSTEMI were slightly attenuated and were no longer significant in the subgroups of patients with and without diabetes. A small proportion of those with diabetes (5.2%) received subcutaneous insulin with oral medication prior to admission; in a further sensitivity analysis we found that excluding this group also had no significant impact on the overall results (see Table e3 ).
Discussion
This study, based on data from a national registry, showed that as used in contemporary clinical practice, survival benefit from the use of insulin infusions for hyperglycaemia did not extend to all ACS but was limited to STEMI. This resulted from a 23% better adjusted survival outcome at 7 days for STEMI without known diabetes, while for STEMI with known type 2 diabetes survival for those having IVII and routine care did not differ. For NSTEMI, use of IVII was associated with worse outcomes than routine care. The difference in response to IVII between STEMI and NSTEMI was marked; an interaction analysis showed the survival benefit effect from IVII was significantly more powerful for those having STEMI than for NSTEMI. We used propensity matched analysis for this study because of the important differences in clinical characteristics between those receiving intravenous insulin and those who did not. The propensity score provided a measure of the likelihood that a patient would receive IVII in the light of their clinical characteristics, such as the admission blood glucose, type of myocardial infarction, pre-existing diabetes status and other previous medical history. This allowed the distribution of covariates to be closely balanced between those having IVII and those who did not, allowing an unbiased assessment of the treatment effect of IVII.
There is a strong patho-physiological basis for the toxicity of hyperglycaemia in ACS, mediated through adverse effects on oxidative stress, 19, 20 platelet activation and thrombin formation 21 and impaired responses to antiplatelet drugs. 22 This makes timely glucose control with insulin a plausible clinical approach. However, to date, the evidence for survival benefit from the use of IVII to normalise raised blood glucose is weak and is based on a single randomised study that examined the combined effects of intravenous insulin in hospital and 3 months of intense post-discharge glycaemic control, in a population comprised predominantly of patients with previously diagnosed diabetes. 7 It remains uncertain to what extent the reported benefit at 1 year was due to intense glycaemic control after discharge and how much was due to the insulin infusion. Two other studies failed to show survival benefit for IVII. 8, 9 A recent randomised open label study of intensive glycaemic control with insulin in a cohort largely of STEMI patients (85%) and predominantly without known diabetes (90%) showed a statistically insignificant reduction in infarct size (assessed by cardiac enzyme release and myocardial perfusion scintigraphy) compared with routine care, despite those having insulin achieving significantly lower blood glucose values. 23 However, mean admission blood glucose in that study was less than 10 mmol/l, which might have limited the potential for benefit. Evidence for survival benefit from IVII alone is therefore limited to a small observational study from a cohort without prior diabetes presenting with a blood glucose >= 11 mmol/l. 24 This showed findings consistent with the present study; a difference in effect of IVII between STEMI and NSTEMI, with survival benefit seen only for STEMI. In addition to the evidential limitations, the definition and management of ACS has changed greatly since publication of DIGAMI 1 7 in 1995 and these factors may influence the response to IVII. In particular the development of troponin assays of increasing sensitivity has greatly increased the numbers of smaller infarctions now recognised as NSTEMI. Primary PCI accompanied by use of increasingly effective anti-platelet and anti-thrombotic medication is now the reperfusion treatment of choice for STEMI, 25 while for NSTEMI angiography and, where appropriate, coronary intervention are now mandated. Furthermore, the extensive use of angiotensin receptor inhibitors and statins prior to admission may favourably influence early outcome independently of any intervention with insulin, by their effects on the no-reflow phenomenon. 26, 27 These interventions may be sufficiently powerful to attenuate any effects of IVII, especially for NSTEMI where infarct size is smaller and early mortality lower.
Our findings show that while there was, overall, a small survival benefit for all STEMI having IVII, this was entirely driven by the survival benefit for STEMI in those who were not known to have diabetes. For STEMI with type 2 diabetes outcome was similar to routine care, although the confidence limits did not exclude the possibility of a small benefit. The difference in response between those with and those without known diabetes may reflect the beneficial effect of glycaemic control provided by oral diabetic medication during the critical early phase of infarction attenuating any further benefit from IVII. Furthermore, metformin, the recommended first-line oral medication in American, European 28 and United Kingdom guidelines, 29 has additional beneficial in vitro cardio-protective effects. 30 Patients with STEMI and type 2 diabetes undergoing primary PCI who were taking metformin before admission had a lower frequency of the no-reflow phenomenon, and had smaller infarctions than those taking other oral diabetic medications. 31, 32 For NSTEMI, whether or not patients had a prior diagnosis of type 2 diabetes, these analyses favoured routine care over IVII. The findings are similar to those in the DIGAMI 2 study, 8 where routine care for a population with type 2 diabetes and either STEMI or NSTEMI showed an early and continuing trend towards lower mortality when compared with those having IVII. The potentially adverse effects of insulin-induced hypoglycaemia may be relevant. [33] [34] [35] While longer term studies using intensive glucose control regimes have demonstrated a relationship between frequency of hypoglycaemic episodes and all-cause mortality, 36, 37 an association between insulin-induced hypoglycaemia and adverse mortality outcomes in ACS has not been confirmed in two studies. 38, 39 However, neither of these studies distinguished between STEMI and NSTEMI, and given the strikingly different responses to IVII of STEMI and NSTEMI in the present study, an association between insulin-induced hypoglycaemia and adverse outcomes for NSTEMI cannot be excluded. Insulin infusions for severely ill patients in the ITU setting, while not necessarily comparable to acute myocardial ischaemia, were initially designed to achieve a target glucose range of 4.4-6 mmol/l, 40 until concern about the adverse effects of hypoglycaemia on mortality encouraged a relaxation of this target. 41 If an intensive glucose target was adopted by clinicians using the DIGAMI regime, where hypoglycaemia rates of 15% were reported, 7 this might have resulted in adverse outcomes amongst those having IVII, particularly amongst those already receiving oral medication for diabetes.
Limitations
This large database inevitably had missing data. After excluding patients who had missing data in any of the variables used for adjustment, we found that the effects of IVII were broadly similar when compared to analyses that included all matched patients, although for NSTEMI the survival benefit of routine care for subsets with and without prior diabetes was slightly attenuated and no longer statistically significant (see Tables e2 and e3 of online data). The more general issue of the applicability of propensity matching techniques and their relationship to randomised trials has recently been addressed 42 and may be relevant to this study; propensity matched studies may produce treatment effect estimates that are more extreme than those in randomised controlled trials, although the differences are rarely significant. In addition, the timing of the insulin infusion in relation to the onset of symptoms, which may be very important, was not routinely recorded. However, from 2010 onwards treatment delay was recorded in the MINAP database in a group of patients with hyperglycaemia having ACS (n= 776) in 40 hospitals as part of the evaluation of a new intravenous insulin regime. This provides an indication of contemporary practice (MINAP data on file); the median delay from arrival in hospital to insulin infusion was 4.3 h (IQR 2.6-7.7 h). We also considered the risk of survivor bias from deaths occurring very early after admission, before insulin treatment could be started. However, in previous work we have shown that when deaths within 24 hours of admission were excluded, 7 and 30 day adjusted outcomes were only slightly attenuated. 24 . Finally, we do not have a record of the frequency of hypoglycaemic episodes, which may be of relevance to mortality outcome for NSTEMI.
Conclusion
We have shown that, in current clinical practice, responses to IVII differ substantially between those with STEMI and NSTEMI, and that responses to IVII by those with STEMI known to have diabetes differ from those without known diabetes. If confirmed, these observational findings have important implications for clinical practice. At present, our findings can only support the routine use of IVII in STEMI without a prior diagnosis of diabetes and show that the use of IVII may do more harm than good in those with NSTEMI.
